A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA

癌症是欧洲人的主要死因之一。胰腺癌(PC)和胆道癌(BTC)是一种罕见的胃肠道腺癌，发病率呈上升趋势，特别是在欧洲人口老龄化的老年人和妇女中，预后不良构成了重大的临床挑战和公共卫生负担。低温大气压等离子体(CAP)在实验室环境中已显示出对各种癌症类型的潜在消退作用。由于其性质，CAP是一种独特的高浓度反应性自由基、电子、离子、紫外线等来源，可在活体组织中引发各种效应。CAP显示了对癌细胞治疗的选择性，而对健康细胞的影响最小；这使得血浆适合于治疗非常敏感的区域或器官中的癌症，在这些区域或器官中，存在未满足的将损害/副作用降至最低的需要。CAP可通过可变长度的介电管输送，这使其成为微创和精确的腹腔镜和内窥镜手术的理想选择。尽管这一概念具有巨大的前景和潜力，但目前市场上还没有一个基于CAP的单一的腹腔镜或内窥镜医疗平台来治疗癌症。该项目提出了一种使用尖端等离子技术、硅内模型和系统级方法的新解决方案。它将把血浆和肿瘤的多尺度模拟结合起来，并将从手术前诊断中获取输入，以进行硅内模型初始化和CAP操作窗口确定。开发的技术将通过体内实验进行演示，同时该项目将为基于CAP的PC/BTCs护理的临床试验和市场推介奠定基础。

Cancer is one of the major causes of death in Europe. Pancreatic (PC) and biliary tract (BTC) cancer are rare gastrointestinal adenocarcinomas with an increasing incidence particularly among the elderly and women in an ageing European population, and a poor prognosis poses major clinical challenges and public health burden. Cold atmospheric pressure plasma (CAP) has shown potential regressing various cancer types in the laboratory setting. Owing to their properties, CAP is a unique source of high concentrations of reactive radicals, electrons, ions, UV etc. that may induce various effects in living tissue. CAP has shown selectivity in where cancer cells are treated with minimal effect to healthy ones; this renders plasma suitable to treat carcinomas in very sensitive areas or organs where an unmet need to minimise damage/side-effects exists. CAP can be delivered through dielectric tubes of variable length, which makes it ideal for minimally invasive and precise laparoscopic and endoscopic operations. Despite the great promise and potential of this concept, there is no single laparoscopic or endoscopic medical platform in the market today based on CAP to treat carcinomas. This project proposes a novel solution using cutting-edge plasma technology, in-silico models, and a system-level approach. It will combine plasma with tumour multiscale simulations and will take input from pre-surgery diagnostics for in-silico model initialisation and CAP operational window determination. The developed technology will be demonstrated through in-vivo experiments, while the foundations for clinical trials and market introduction for CAP-based care of PC/BTCs will be laid out in this project.